Investors
We maintain a transparent, comprehensive dialogue with the financial community about our strategy, outlook, financial data, economic environment, and social impact.
Second Quarter 2025
Second quarter 2025 results were reviewed by management during a live audio webcast with the financial community on July 31, 2025. The presentation was followed by a Q&A session.
Press Releases
August 14, 2025
Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease
August 6, 2025
Press Release: Sanofi completes the acquisition of Vigil Neuroscience, Inc.
July 31, 2025
Press release: Online availability of Sanofi’s half-year financial report for 2025
Upcoming Events
30th Consecutive Year of Dividend Increase
Environment, Social, Governance
As a global pharmaceutical company, we stretch everyday to deliver safe and sustainable innovation and play our part in addressing some of the world’s most pressing challenges.
Contact Our Investor Relations Team
For general inquiries
Please contact the switchboard, +33 (0)1 53 77 40 00